Top Markets
Coin of the day
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
株式のランク #40868
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
株価
$0.02765
最終同期: 2024-12-23
時価総額
$69.04K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Histogen Inc. (HSTO)

カテゴリー

Histogen Inc.(HSTO)の収益
Sep 2023 時点の収益 TTM: $19.00K
Histogen Inc. の最新の財務報告によると、現在の収益 (TTM) は $19.00K です。2021 年には $919.00K の収益があり、これは 2020 年の $2.06M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Histogen Inc. の収益履歴(2011 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $19.00K -99.50%
2022 $3.77M 310.12%
2021 $919.00K -55.37%
2020 $2.06M -82.02%
2019 $11.45M -65.90%
2018 $33.59M -5.06%
2017 $35.38M 4,327.40%
2016 $799.05K 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B 66,443,584.21%
US
$6.02B 31,690,885.84%
NL
- -
CH
- -
KR
$10.11B 53,214,566.82%
BE